Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis

Résumé détaillé
- PROT-001, the company's investigational oral small molecule drug for AL amyloidosis, demonstrated an acceptable safety and tolerability profile in a healthy volunteer Phase 1…
- In human cardiomyocyte and plasma cell studies, PROT-001 reduced markers of stress and toxicity, and demonstrated compatibility with standard-of-care bortezomib
- Additional presentations highlight advanced detection of amyloidogenic light chains with Protego's AmyLiteDxTM assay, and use of NT-proBNP as an early clinical biomarker of cardiac response
- Results support evaluating PROT-001 in planned Phase 2/3 SHIELD-AL study in AL amyloidosis patients
SAN DIEGO, Nov. 16, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced results from five presentations that highlight the Phase I clinical and preclinical profile of PROT-001, the company's potential first-in-class, investigational lambda light chain kinetic stabilizer to treat light chain (AL) amyloidosis.
PROT-001 is designed as a kinetic stabilizer of amyloidogenic light chains (LCs) and to neutralize their toxicity. Across the five ISA 2026 presentations, Protego presented data that, collectively, support the advancement of PROT-001 into pivotal studies.
"Cardiac involvement is a major driver of morbidity and mortality in AL amyloidosis. Plasma cell-directed therapies reduce the production of light chains, but circulating amyloidogenic light chains can continue to damage the heart," said Brent J. Warner, MBA, Chief Executive Officer of Protego. "PROT-001 is designed to complement these treatments by stabilizing amyloidogenic light chains and reducing their toxicity. The data presented at ISA 2026 strengthen the rationale for SHIELD-AL, where we will evaluate whether this approach can deliver earlier and deeper cardiac responses."
Detailed results from Protego's five poster presentations are as follows:
PROT-001, a first-in-class lambda light chain kinetic stabilizer for AL amyloidosis: Results from the Phase I PRO-1A-101 Study (Abstract 32458)PRO-1A-101 evaluated the safety, tolerability…
In the study…
Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)
